Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos

Yıl: 2019 Cilt: 27 Sayı: 3 Sayfa Aralığı: 374 - 380 Metin Dili: İngilizce DOI: 10.5606/tgkdc.dergisi.2019.17557 İndeks Tarihi: 27-05-2020

Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos

Öz:
Background: In this study, we aimed to compare serum biochemicalmarkers in patients with malignant pleural mesothelioma and pleuralplaques versus healthy individuals exposed to environmental asbestos.Methods: Between September 01, 2010 and March 31, 2011, a totalof 540 participants (354 males, 186 females; mean age 61.4 years;range, 35 to 89 years) were included in the study. The participantswere divided into four groups as follows: (1) patients with pleuralplaques (n=277); (2) healthy individuals with normal chest X-rayswho were exposed to environmental asbestos (n=121); (3) healthyindividuals with normal chest X-rays who were not exposed toenvironmental asbestos (n=118); and (4) patients with malignantpleural mesothelioma (n=24). Serum levels of carcinoembryonicantigen, cancer antigen 125, 15-3, 19-9, free T3, free T4, thyroidstimulatinghormone, vitamin B12, folate, and ferritin were measured.Results: Serum cancer antigen 125, 15-3, folic acid, vitaminB12, and ferritin levels were higher with lower free T3 levels inGroup 4 than the other groups. The areas under the curve forcancer antigen 125 and 15-3 were 0.78 and 0.67, respectively inthe differential diagnosis of mesothelioma from other pathologies(p<0.001 for both). Optimal limits of these biomarkers were13.63 and 18.43 ng/mL, respectively with 83% and 75% sensitivityand 69% and 48% specificity, respectively.Conclusion: The combination or individual use of serum cancerantigen 125, 15-3, folic acid, vitamin B12, and ferritin levels maybe helpful for early diagnosis and treatment of malignant pleuralmesothelioma.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi Cerrahi

Mezotelyoma ve plevral plaklı hastaların çevresel asbest maruziyeti yaşamış sağlıklı bireylere kıyasla serum biyokimyasal belirteçlerin karşılaştırılması

Öz:
Amaç: Bu çalışmada mezotelyoma ve plevral plaklı hastaların çevresel asbest maruziyeti yaşamış sağlıklı bireylere kıyasla serum biyokimyasal belirteçleri karşılaştırıldı. Çalışma planı: 01 Eylül 2010 - 31 Mart 2011 tarihleri arasında toplam 540 katılımcı (354 erkek, 186 kadın; ort. yaş 61.4 yıl; dağılım, 35-89 yıl) çalışmaya alındı. Katılımcılar dört gruba ayrıldı: (1) plevral plaklı hastalar (n=277); (2) çevresel asbeste maruz kalıp göğüs röntgenleri normal olan sağlıklı bireyler (n=121); (3) çevresel asbeste maruz kalmadan göğüs röntgenleri normal olan sağlıklı bireyler (n=118) ve (4) malign plevral mezotelyomalı hastalar (n=24). Serumda karsinoembriyonik antijen, kanser antijeni 125, 15-3, 19-9, serbest T3, serbest T4, tiroid stimülan hormon, B12 vitamini, folik asit ve ferritin düzeyleri ölçüldü. Bulgular: Diğer gruplara kıyasla, Grup 4’te serum kanser antijeni 125, 15-3, folik asit, B12 vitamini ve ferritin düzeyleri daha yüksek ve serbest T3 düzeyleri daha düşük idi. Mezotelyomanın diğer patolojilerden ayırıcı tanısında kanser antijeni 125 ve 15-3’ün eğri altında kalan alanı sırasıyla 0.78 ve 0.67 idi (her ikisi için de p<0.001). Bu biyobelirteçlerin optimum sınırı sırasıyla 13.63 ve 18.43 ng/mL olup, duyarlılıkları sırasıyla %83 ve %75 ve özgüllükleri %69 ve %48 idi. Sonuç: Serum kanser antijeni 125, 15-3, folik asit, B12 vitamini ve ferritin düzeylerinin birlikte veya tek başına kullanımı, malign plevral mezotelyomanın erken tanı ve tedavisinde yararlı olabilir.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
3
3
3
  • 1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
  • 2. Helland Å, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in norway: a populationbased study of 1686 cases. J Thorac Oncol 2012;7:1858-61.
  • 3. Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, et al. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. Eur J Surg Oncol 2018;44:792-8.
  • 4. Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung 2014;192:197-203.
  • 5. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012;367:1417-27.
  • 6. Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S, et al. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J Thorac Dis 2013;5:145-8.
  • 7. Bayram M, Dongel I, Bakan ND, Yalççn H, Cevit R, Dumortier P, et al. High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites. Chest 2013;143:164-71.
  • 8. Berk S, Yalcin H, Dogan OT, Epozturk K, Akkurt I, Seyfikli Z. The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey. Environ Geochem Health 2014;36:55-64.
  • 9. Dumortier P, Coplü L, de Maertelaer V, Emri S, Baris I, De Vuyst P. Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. Am J Respir Crit Care Med 1998;158:1815-24.
  • 10. Döngel I, Bayram M, Bakan ND, Yalçın H, Gültürk S. Is living close to ophiolites related to asbestos related diseases? Cross-sectional study. Respir Med 2013;107:870-4.
  • 11. Brims FJ, Lee YC, Creaney J. The continual search for ideal biomarkers for mesothelioma: the hurdles. J Thorac Dis 2013;5:364-6.
  • 12. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
  • 13. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, et al. Serum levels of soluble mesothelinrelated peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646-50.
  • 14. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 2011;85:185-92.
  • 15. Wang XF, Wu YH, Wang MS, Wang YS. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev 2014;15:363-8.
  • 16. Antonangelo L, Sales RK, Corá AP, Acencio MM, Teixeira LR, Vargas FS. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results. Curr Oncol 2015;22:336-41.
  • 17. Sezgi C, Taylan M, Sen HS, Evliyaoğlu O, Kaya H, Abakay O, et al. Oxidative status and acute phase reactants in patients with environmental asbestos exposure and mesothelioma. ScientificWorldJournal 2014;2014:902748.
  • 18. Milman N, Pedersen LM. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer. Oncol Rep 2002;9:193-8.
  • 19. Chiche L, Jean R, Romain F, Roux F, Thomas G, Canavese S, et al. Clinical implications of high cobalamin blood levels for internal medicine. Rev Med Interne 2008;29:187-94. [Abstract]
  • 20. Andrès E, Serraj K, Zhu J, Vermorken AJ. The pathophysiology of elevated vitamin B12 in clinical practice. QJM 2013;106:505-15.
  • 21. Oh HK, Lee JY, Eo WK, Yoon SW, Han SN. Elevated Serum Vitamin B12 Levels as a Prognostic Factor for Survival Time in Metastatic Cancer Patients: A Retrospective Study. Nutr Cancer 2018;70:37-44.
  • 22. Aloreidi K, Zamulko A. Elevated Vitamin B12: A Rare Presentation for Gallbladder Adenocarcinoma. S D Med 2018;71:171-3.
  • 23. Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 2017;116:731-41.
  • 24. Bonotti A, Foddis R, Landi S, Melaiu O, De Santi C, Giusti L, et al. A Novel Panel of Serum Biomarkers for MPM Diagnosis. Dis Markers 2017;2017:3510984.
  • 25. Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis 2018;10:353-9.
  • 26. Nakayama K, Seike M, Noro R, Takeuchi S, Matsuda K, Kunugi S, et al. Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma. Anticancer Res 2019;39:627-33.
  • 27. Gao R, Wang F, Wang Z, Wu Y, Xu L, Qin Y, et al. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis. Medicine (Baltimore) 2019;98:14979.
APA DÖNGEL İ, Akbaş A, BENLİ İ, Bayram M (2019). Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. , 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
Chicago DÖNGEL İSA,Akbaş Ali,BENLİ İsmail,Bayram Mehmet Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. (2019): 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
MLA DÖNGEL İSA,Akbaş Ali,BENLİ İsmail,Bayram Mehmet Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. , 2019, ss.374 - 380. 10.5606/tgkdc.dergisi.2019.17557
AMA DÖNGEL İ,Akbaş A,BENLİ İ,Bayram M Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. . 2019; 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
Vancouver DÖNGEL İ,Akbaş A,BENLİ İ,Bayram M Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. . 2019; 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
IEEE DÖNGEL İ,Akbaş A,BENLİ İ,Bayram M "Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos." , ss.374 - 380, 2019. 10.5606/tgkdc.dergisi.2019.17557
ISNAD DÖNGEL, İSA vd. "Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos". (2019), 374-380. https://doi.org/10.5606/tgkdc.dergisi.2019.17557
APA DÖNGEL İ, Akbaş A, BENLİ İ, Bayram M (2019). Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. Türk Göğüs Kalp Damar Cerrahisi Dergisi, 27(3), 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
Chicago DÖNGEL İSA,Akbaş Ali,BENLİ İsmail,Bayram Mehmet Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. Türk Göğüs Kalp Damar Cerrahisi Dergisi 27, no.3 (2019): 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
MLA DÖNGEL İSA,Akbaş Ali,BENLİ İsmail,Bayram Mehmet Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. Türk Göğüs Kalp Damar Cerrahisi Dergisi, vol.27, no.3, 2019, ss.374 - 380. 10.5606/tgkdc.dergisi.2019.17557
AMA DÖNGEL İ,Akbaş A,BENLİ İ,Bayram M Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. Türk Göğüs Kalp Damar Cerrahisi Dergisi. 2019; 27(3): 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
Vancouver DÖNGEL İ,Akbaş A,BENLİ İ,Bayram M Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. Türk Göğüs Kalp Damar Cerrahisi Dergisi. 2019; 27(3): 374 - 380. 10.5606/tgkdc.dergisi.2019.17557
IEEE DÖNGEL İ,Akbaş A,BENLİ İ,Bayram M "Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos." Türk Göğüs Kalp Damar Cerrahisi Dergisi, 27, ss.374 - 380, 2019. 10.5606/tgkdc.dergisi.2019.17557
ISNAD DÖNGEL, İSA vd. "Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos". Türk Göğüs Kalp Damar Cerrahisi Dergisi 27/3 (2019), 374-380. https://doi.org/10.5606/tgkdc.dergisi.2019.17557